Literature DB >> 14499674

Expression and immunolocalisation of neutral endopeptidase in prostate cancer.

Martin Albrecht1, Anja Mittler, Beate Wilhelm, Ake Lundwall, Hans Lilja, Gerhard Aumüller, Anders Bjartell.   

Abstract

BACKGROUND: Neutral Endopeptidase (NEP) is a cell surface enzyme that cleaves and inactivates neuropeptides. When present on androgen-dependent prostate cancer (PC) cells, NEP inactivates growth stimulatory neuropeptides. After androgen ablation NEP expression decreases and neuropeptides can enhance cell growth, leading to the development of androgen-independent, neuropeptide stimulated PC. Aim of the study was to analyse the expression, localisation and distribution of NEP in benign and malignant prostatic tissues and its relation to the cytoskeleton.
METHODS: Immunohistochemistry (IHC) was performed to localise NEP in fixed specimens from normal prostatic tissue, benign prostate hyperplasia (BPH) and PC of Gleason grade 2-5. In situ hybridisation and Western blotting experiments were carried out to confirm NEP gene expression and translation to mature protein in BPH and PC tissue. Confocal laser scanning microscopy was utilised to investigate whether development of high grade prostate tumours was accompanied by changes in intracellular actin/NEP colocalisation patterns. Finally, the proliferative activity in relation to loss of NEP expression was investigated by dual staining of NEP and Ki-67 in prostatic tumours.
RESULTS: In situ hybridisation studies revealed preserved expression of NEP mRNA in epithelial cells of PC. NEP was by IHC shown to be located in the apical plasma membrane of normal epithelial cells and BPH tissue. In PC a Gleason grade dependent shift of the NEP distribution pattern towards a heterogeneous, partly cytoplasmic allocation of the protein was found. Compared to BPH tissue, specimens derived from PC showed very low IHC-staining intensity for NEP protein. In high grade PC the typical apical colocalisation of actin and NEP was lost and a strong granular cytoplasmic NEP staining was found. PC areas with a high expression of NEP displayed diminished proliferative activity i.e. low staining intensity for Ki-67.
CONCLUSIONS: NEP is differentially expressed in the normal and the pathologically altered prostate with a clear shift from a membrane bound to a cytoplasmic distribution pattern in high-grade tumours and loss of NEP expression in areas of high proliferative activity. The data presented support an active involvement of NEP in the progression of androgen-independent PC. Further studies are needed to unravel the mechanisms underlying the cytoplasmic NEP distribution in PC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499674     DOI: 10.1016/s0302-2838(03)00322-1

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  4 in total

1.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma.

Authors:  Lawrence True; Ilsa Coleman; Sarah Hawley; Ching-Ying Huang; David Gifford; Roger Coleman; Tomasz M Beer; Edward Gelmann; Milton Datta; Elahe Mostaghel; Beatrice Knudsen; Paul Lange; Robert Vessella; Daniel Lin; Leroy Hood; Peter S Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-07       Impact factor: 11.205

2.  Neutral endopeptidase is a myristoylated protein.

Authors:  Rong Zheng; Akio Horiguchi; Katsuyuki Iida; Jungoo Lee; Ruoqian Shen; Oscar B Goodman; David M Nanus
Journal:  Mol Cell Biochem       Date:  2009-09-15       Impact factor: 3.396

3.  Differential expression of CD10 in prostate cancer and its clinical implication.

Authors:  Marc A Dall'Era; Lawrence D True; Andrew F Siegel; Michael P Porter; Tracy M Sherertz; Alvin Y Liu
Journal:  BMC Urol       Date:  2007-03-02       Impact factor: 2.264

4.  Study the Expression of CD10 in Prostate Carcinoma and its Correlation with Various Clinicopathological Parameters.

Authors:  Lalit Singh; Nisha Marwah; Namita Bhutani; Devendra Pawar; Raman Kapil; Rajeev Sen
Journal:  Iran J Pathol       Date:  2019-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.